Evidence supporting the use of: Marine lipid (unspecified)
For the health condition: Congestive Heart Failure

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Marine lipids, particularly omega-3 polyunsaturated fatty acids (PUFAs) such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been evaluated for their potential benefits in congestive heart failure (CHF). Evidence from clinical studies suggests that omega-3 PUFAs may provide modest improvements in cardiovascular outcomes for patients with heart failure. The most notable study is the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza cardiaca-Heart Failure) trial, a large randomized controlled trial that demonstrated a small but statistically significant reduction in all-cause mortality and cardiovascular hospitalizations in CHF patients supplemented with omega-3 PUFAs compared to placebo.

Proposed mechanisms include anti-inflammatory effects, anti-arrhythmic properties, and improvements in endothelial function. However, the overall magnitude of benefit is modest, and not all studies have shown consistent results. Current heart failure management guidelines (such as those from the American College of Cardiology and American Heart Association) suggest that omega-3 PUFA supplementation "may be considered" for patients with heart failure to reduce mortality and cardiovascular hospitalizations, but it is not a core or primary therapy. Thus, while there is scientific validation for some effect, the strength of evidence is moderate at best, and marine lipids are considered an adjunct rather than a primary treatment for CHF.

More about Marine lipid (unspecified)
More about Congestive Heart Failure

Products containing Marine lipid (unspecified)

We currently have no products on Caring Sunshine that contain this ingredient.